DDI-MedLine.d211.s0 >> Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. >> 17-28,34-40,99-110,112-118
DDI-MedLine.d211.s1 >> Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. >> 127-139
DDI-MedLine.d211.s2 >> The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM. >> 31-42,68-74
